Efficacy of catheter ablation for patients with atrial fibrillation and atrial septal defect. (9th January 2021)

• Record Type: Journal Article
• Authors: Ogiso, Masataka; Ejima, Koichiro; Shoda, Morio; Sugiyama, Hisashi; Kato, Ken; Tanaka, Hiroyuki; Ohki, Hirotaka; Miura, Masaru; Hagiwara, Nobuhisa
• Is Part Of: Journal of cardiovascular electrophysiology. Volume 32:Number 2(2021)
• Page Start: 279
• Page End: 286
• Publication Date: 2021-01-09
• Subjects: atrial fibrillation -- atrial septal defect -- atrial septal defect device closure -- catheter ablation -- paroxysmal atrial fibrillation -- structural heart disease; Blood vessels -- Physiology -- Periodicals; Electrophysiology -- Periodicals; Heart -- Physiology -- Periodicals; 612.1
• DOI: 10.1111/jce.14862
• Languages: English
• ISSNs: 1045-3873

Abstract

Abstract: Introduction: Given that few studies investigated the efficacy of catheter ablation (CA) in patients with paroxysmal atrial fibrillation (AF) and atrial septal defect (ASD), this study evaluated its effectiveness in patients with paroxysmal AF and ASD. Methods and Results: Of the 216 patients who underwent ASD device closure at two hospitals, 36 patients had paroxysmal AF. After April 2012, CA for AF was performed before ASD device closure (ASD‐CA group; n = 20). The ASD‐CA group had a significantly higher AF‐free survival rate after ASD device closure compared to patients without CA for AF before ASD device closure (ASD‐non‐CA group; n = 16) (ASD‐CA group: 2 patients vs. ASD‐non‐CA group: 9 patients; follow‐up period: 4.2 ± 2.5 years; log‐rank p = .01). In addition, the AF‐free survival rates were similar between the ASD‐CA group and 80 paroxysmal AF patients who underwent CA without any detectable structural heart disease (non‐SHD‐CA group). The two groups were matched by propensity scores for age, sex, and left atrium dimension (ASD‐CA group: 2 patients vs. non‐SHD‐CA group: 5 patients; follow‐up period: 3.3 ± 1.8 years; log‐rank p = .28). Conclusion: CA for AF before ASD device closure might be an effective treatment option for patients with paroxysmal AF and ASD.